Clinical trial
SU006668 in Treating Patients With Advanced Solid Tumors
NCT00024063 · Jonsson Comprehensive Cancer Center, Other · Unknown status
Key facts
| NCT number | NCT00024063 |
|---|---|
| Title | SU006668 in Treating Patients With Advanced Solid Tumors |
| Official title | A Phase I Study Of SU006668 Via Twice Daily Oral Administration Under Fed Conditions In Patients With Advanced Malignancies |
| Lead sponsor | Jonsson Comprehensive Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Unknown status |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Breast Cancer, Colorectal Cancer, Gastric Cancer, Kidney Cancer, Lung Cancer, Multiple Myeloma and Plasma Cell Neoplasm, Pancreatic Cancer, Prostate Cancer |
| Intervention type | Drug |
| Interventions | orantinib |
| First posted | Apr 6, 2004 |
| Last update posted | Dec 19, 2013 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: